Skip to content

Bioequivalance study of Famotidine 40 mg

Bioequivalance study of Famotidine 40 mg tablets manufactured by Fatak Chemie pars pharmaceutical company on 24 healthy volunteers and comparing pharmacokinetics results with famotidine tablets manufactured by Ratiopharm.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200513047423N5
Enrollment
24
Registered
2021-11-29
Start date
2021-11-05
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalance Famotidine 40 mg.

Interventions

Intervention 1: Intervention group 1: One Famotidine 40 mg tablet manufactured by Fatak chemie pars company (Test drug) is administrated to each of 12 healthy volunteer of group 1. Intervention 2: In

Sponsors

Fatak chemie pars Pharmacy
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Healthy liver Healthy kidney Volunteers should not be too fat or too thin and their weight index should be in the appropriate range

Exclusion criteria

Exclusion criteria: Out of age ranges smoking pragnancy

Design outcomes

Primary

MeasureTime frame
Plasma concentration changing after administration of Famotidine tablet.Plasma concentration of famotidine at Tmax reaches about 200 ng/mL and its measurement range is from 10ng / mL to 700ng / mL. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each volunteers. Hence the Tmax of Famotidine is between 1 and 3 hours, so it is needed to have 5 blood sampling before Tmax. This period of time is called absorption phase. In the elimination phase (after Tmax) blood sampling carry out each hours. Method of measurement: In this study, the variable is plasma concentration of famotidine. High performance liquid chromatography is used to determine the concentration of famotidine in plasma.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir mehdizahed

Ofoqh pharmed labratory

A_mehdizadeh@gmail.com+98 21 6673 8727

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026